<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Protocol PRO001 v2.1</title>
    <style>
        body {
            font-family: Arial, sans-serif;
            line-height: 1.6;
            margin: 40px;
            color: #333;
        }
        h1 {
            color: #1a5276;
            border-bottom: 2px solid #3498db;
            padding-bottom: 10px;
        }
        h2 {
            color: #2874a6;
            margin-top: 30px;
        }
        h3 {
            color: #2e86c1;
        }
        .content {
            max-width: 800px;
            margin: 0 auto;
        }
        ul {
            margin-left: 20px;
        }
        li {
            margin-bottom: 8px;
        }
        .header {
            text-align: center;
            margin-bottom: 40px;
        }
        .footer {
            margin-top: 50px;
            border-top: 1px solid #ddd;
            padding-top: 20px;
            font-size: 12px;
            color: #777;
            text-align: center;
        }
    </style>
</head>
<body>
    <div class="content">
        <div class="header">
            <h1>Clinical Trial Protocol PRO001</h1>
            <p>Protocol Number: PRO001</p>
            <p>Version: 2.1</p>
            <p>Date: January 15, 2025</p>
        </div>

        <h2>1. Protocol Summary</h2>
        <p>This clinical trial protocol outlines the procedures and methodologies for assessing the efficacy and safety of the investigational product in patients with Type 2 Diabetes.</p>

        <h2>2. Study Objectives and Endpoints</h2>
        <h3>2.1 Primary Objective</h3>
        <p>To evaluate the efficacy of the investigational product in reducing HbA1c levels compared to placebo in adults with Type 2 Diabetes.</p>
        
        <h3>2.2 Secondary Objectives</h3>
        <ul>
            <li>To assess changes in fasting plasma glucose levels</li>
            <li>To evaluate changes in body weight</li>
            <li>To assess insulin sensitivity and beta-cell function</li>
        </ul>
        
        <h3>2.3 Primary Endpoint</h3>
        <p>Change from baseline in HbA1c at Week 24.</p>
        
        <h3>2.4 Secondary Endpoints</h3>
        <ul>
            <li>Change from baseline in fasting plasma glucose at Week 24</li>
            <li>Change from baseline in body weight at Week 24</li>
            <li>Proportion of patients achieving HbA1c &lt;7.0% at Week 24</li>
        </ul>

        <h2>3. Study Design and Procedures</h2>
        <p>This is a Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter study in adult patients with Type 2 Diabetes.</p>
        
        <h3>3.1 Study Duration</h3>
        <p>The total duration of the study is approximately 30 weeks, consisting of a 4-week screening period, a 24-week treatment period, and a 2-week follow-up period.</p>
        
        <h3>3.2 Study Visits</h3>
        <p>Study visits will occur at Screening, Baseline (Day 1), Weeks 4, 8, 12, 16, 20, 24, and Follow-up (Week 26).</p>

        <h2>4. Patient Eligibility Criteria</h2>
        <h3>4.1 Inclusion Criteria</h3>
        <ul>
            <li>Male or female, age 18 to 75 years, inclusive</li>
            <li>Diagnosis of Type 2 Diabetes for at least 6 months prior to screening</li>
            <li>HbA1c ≥7.0% and ≤10.0% at screening</li>
            <li>Body Mass Index (BMI) ≥23 kg/m² and ≤40 kg/m² at screening</li>
        </ul>
        
        <h3>4.2 Exclusion Criteria</h3>
        <ul>
            <li>Diagnosis of type 1 diabetes mellitus</li>
            <li>History of diabetic ketoacidosis</li>
            <li>Treatment with insulin within 3 months prior to screening</li>
            <li>Significant renal, hepatic, or cardiovascular disease</li>
        </ul>

        <h2>5. Treatment Administration</h2>
        <p>Patients will be randomized 1:1 to receive either the investigational product or placebo once daily for 24 weeks.</p>

        <h2>6. Safety Monitoring</h2>
        <p>Safety assessments will include adverse event monitoring, physical examinations, vital signs, ECGs, and laboratory assessments.</p>

        <h2>7. Statistical Analysis Plan</h2>
        <p>A sample size of 300 patients (150 per treatment arm) will provide 90% power to detect a treatment difference of 0.5% in HbA1c at Week 24 with a two-sided alpha of 0.05.</p>

        <div class="footer">
            <p>© 2025 Clinical Research Organization. All rights reserved.</p>
            <p>This document is confidential and contains proprietary information.</p>
        </div>
    </div>
</body>
</html>